AU2019277382B2 - Methods for increasing sepiapterin plasma exposure - Google Patents

Methods for increasing sepiapterin plasma exposure Download PDF

Info

Publication number
AU2019277382B2
AU2019277382B2 AU2019277382A AU2019277382A AU2019277382B2 AU 2019277382 B2 AU2019277382 B2 AU 2019277382B2 AU 2019277382 A AU2019277382 A AU 2019277382A AU 2019277382 A AU2019277382 A AU 2019277382A AU 2019277382 B2 AU2019277382 B2 AU 2019277382B2
Authority
AU
Australia
Prior art keywords
sepiapterin
administration
food
subject
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019277382A
Other languages
English (en)
Other versions
AU2019277382A1 (en
Inventor
Jonathan Reis
Neil Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics MP Inc
Original Assignee
PTC Therapeutics MP Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics MP Inc filed Critical PTC Therapeutics MP Inc
Publication of AU2019277382A1 publication Critical patent/AU2019277382A1/en
Application granted granted Critical
Publication of AU2019277382B2 publication Critical patent/AU2019277382B2/en
Priority to AU2025200814A priority Critical patent/AU2025200814A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2019277382A 2018-05-30 2019-05-30 Methods for increasing sepiapterin plasma exposure Active AU2019277382B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025200814A AU2025200814A1 (en) 2018-05-30 2025-02-06 Methods for increasing sepiapterin plasma exposure

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862677943P 2018-05-30 2018-05-30
US62/677,943 2018-05-30
US201862771398P 2018-11-26 2018-11-26
US62/771,398 2018-11-26
US201962822376P 2019-03-22 2019-03-22
US62/822,376 2019-03-22
GC2019/37663 2019-05-28
GC201937663 2019-05-28
PCT/US2019/034523 WO2019232130A1 (en) 2018-05-30 2019-05-30 Methods for increasing sepiapterin plasma exposure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025200814A Division AU2025200814A1 (en) 2018-05-30 2025-02-06 Methods for increasing sepiapterin plasma exposure

Publications (2)

Publication Number Publication Date
AU2019277382A1 AU2019277382A1 (en) 2021-01-21
AU2019277382B2 true AU2019277382B2 (en) 2025-01-09

Family

ID=68699037

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019277382A Active AU2019277382B2 (en) 2018-05-30 2019-05-30 Methods for increasing sepiapterin plasma exposure
AU2025200814A Pending AU2025200814A1 (en) 2018-05-30 2025-02-06 Methods for increasing sepiapterin plasma exposure

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025200814A Pending AU2025200814A1 (en) 2018-05-30 2025-02-06 Methods for increasing sepiapterin plasma exposure

Country Status (20)

Country Link
US (3) US11617752B2 (https=)
EP (2) EP3801536B1 (https=)
JP (2) JP7502197B2 (https=)
CN (1) CN112703002A (https=)
AU (2) AU2019277382B2 (https=)
CA (1) CA3102106A1 (https=)
DK (1) DK3801536T3 (https=)
ES (1) ES2986920T3 (https=)
FI (1) FI3801536T3 (https=)
HR (1) HRP20241213T1 (https=)
HU (1) HUE068589T2 (https=)
LT (1) LT3801536T (https=)
MD (1) MD3801536T2 (https=)
MX (2) MX2020012979A (https=)
PL (1) PL3801536T3 (https=)
PT (1) PT3801536T (https=)
RS (1) RS65874B1 (https=)
SI (1) SI3801536T1 (https=)
SM (1) SMT202400430T1 (https=)
WO (1) WO2019232130A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
EP3801536B1 (en) 2018-05-30 2024-07-17 PTC Therapeutics MP, Inc. Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
CN112654356A (zh) 2018-05-30 2021-04-13 Ptc医疗Mp公司 增加四氢生物蝶呤血浆暴露的组合物和方法
CA3165636A1 (en) * 2020-01-24 2021-07-29 Neil Smith Methods for treating parkinson's disease with sepiapterin
US20230077104A1 (en) * 2020-02-19 2023-03-09 The United States Government As Represented By The Department Of Veteran Affairs L-sepiapterin and methods of use for treating diseases and disorders
JP2024506336A (ja) * 2021-02-09 2024-02-13 ピーティーシー セラピューティクス エムピー，インコーポレイテッド 膠芽腫の治療方法
EP4291196A1 (en) * 2021-02-09 2023-12-20 PTC Therapeutics MP, Inc. Methods for treating covid-19 with sepiapterin
CN120732846A (zh) * 2025-04-09 2025-10-03 中南大学湘雅医院 吲哚乙酸在制备预防或治疗高血压产品中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128049A2 (en) * 2007-04-11 2008-10-23 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
US20130197000A1 (en) * 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
WO2019232126A1 (en) * 2018-05-30 2019-12-05 Censa Pharmaceuticals Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) * 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
CA2228970A1 (en) 1995-08-18 1997-02-27 Donald W. Landry Detection of organic compounds through regulation of antibody-catalyzed reactions
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
EP1696877A4 (en) * 2003-11-13 2010-06-09 Gen Hospital Corp PROCESS FOR PAIN TREATMENT
US7732599B2 (en) 2003-11-17 2010-06-08 Biomarin Pharmaceutical Inc. Process for preparing tetrahydrobiopterin and analogs of tetrahydrobiopterin
KR20070005550A (ko) 2003-11-17 2007-01-10 바이오마린 파머수티컬 인크. 대사 장애 치료를 위한 조성물 및 방법
CA2678125C (en) 2003-11-17 2014-10-14 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
WO2006055511A2 (en) 2004-11-17 2006-05-26 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
CA2588994A1 (en) 2004-12-08 2006-06-15 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
US7582799B2 (en) 2005-04-28 2009-09-01 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
US20110144117A1 (en) 2008-08-12 2011-06-16 Orpha Swiss Gmbh Pharmaceutical Dosage Form Containing Tetrahydrobiopterin
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CA2828685C (en) 2011-03-01 2018-05-29 Rubicon Research Private Limited Stable compositions of tetrahydrobiopterin
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
IN2014DN09053A (https=) 2012-05-07 2015-05-22 Shiratori Pharm
US10365267B2 (en) 2014-10-31 2019-07-30 Children's Medical Center Corporation Methods and assays relating to sepiapterin reductase inhibition
US11130760B2 (en) 2016-11-29 2021-09-28 Ptc Therapeutics Mp, Inc. Polymorphic form of sepiapterin
US11072614B2 (en) 2016-11-29 2021-07-27 Ptc Therapeutics Mp, Inc. Polymorphs of sepiapterin and salts thereof
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
KR102895167B1 (ko) * 2017-11-23 2025-12-04 가부시키가이샤 한도오따이 에네루기 켄큐쇼 표시 장치 및 전자 기기
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
EP3801536B1 (en) 2018-05-30 2024-07-17 PTC Therapeutics MP, Inc. Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
IL290321B1 (en) 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128049A2 (en) * 2007-04-11 2008-10-23 Biomarin Pharmaceutical Inc. Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
US20130197000A1 (en) * 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
WO2019232126A1 (en) * 2018-05-30 2019-12-05 Censa Pharmaceuticals Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure

Also Published As

Publication number Publication date
CN112703002A (zh) 2021-04-23
EP3801536A1 (en) 2021-04-14
EP4454704A3 (en) 2025-01-01
US12329757B2 (en) 2025-06-17
MX2020012979A (es) 2021-04-29
EP3801536B1 (en) 2024-07-17
JP2024069192A (ja) 2024-05-21
ES2986920T3 (es) 2024-11-13
LT3801536T (lt) 2024-09-25
HUE068589T2 (hu) 2025-01-28
SMT202400430T1 (it) 2024-11-15
US11617752B2 (en) 2023-04-04
EP3801536A4 (en) 2022-03-23
US20230381181A1 (en) 2023-11-30
EP4454704A2 (en) 2024-10-30
SI3801536T1 (sl) 2024-12-31
MD3801536T2 (ro) 2024-11-30
PL3801536T3 (pl) 2025-02-03
HRP20241213T1 (hr) 2024-11-22
PT3801536T (pt) 2024-09-19
RS65874B1 (sr) 2024-09-30
US20210220363A1 (en) 2021-07-22
FI3801536T3 (fi) 2024-08-29
AU2025200814A1 (en) 2025-02-27
DK3801536T3 (da) 2024-08-19
JP7502197B2 (ja) 2024-06-18
WO2019232130A1 (en) 2019-12-05
MX2024005935A (es) 2024-06-04
JP2021525729A (ja) 2021-09-27
AU2019277382A1 (en) 2021-01-21
CA3102106A1 (en) 2019-12-05
JP7841005B2 (ja) 2026-04-06
US20260091037A1 (en) 2026-04-02

Similar Documents

Publication Publication Date Title
US12329757B2 (en) Methods for increasing sepiapterin plasma exposure
US20250195529A1 (en) Compositions and methods for increasing tetrahydrobiopterin plasma exposure
US12213982B2 (en) Pharmaceutical compositions comprising sepiapterin and uses thereof
AU2019277372B2 (en) Pharmaceutically acceptable salts of sepiapterin
HK40119071A (en) Methods for increasing sepiapterin plasma exposure
HK40051961B (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
HK40051961A (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
BR112020024346A2 (pt) métodos para aumentar a exposição de sepiapterina no plasma
BR112020003865B1 (pt) Composições farmacêuticas compreendendo sepiapterina e usos das mesmas

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)